Welcome to BioSeeker Group!

R&D

In this section you will find R&D market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.

146 Item(s)

per page

Set Ascending Direction
  1. Wnt Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 228 companies plus partners who are today developing 253 Wnt pathway targeting drugs in 935 developmental projects in cancer across 204 different targets. In addition, there are 2 suspended drugs and another 118 drugs where development has been ceased. Learn More

  2. Viral Carcinogenesis Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 246 companies plus partners who are today developing 311 viral carcinogenesis targeting drugs in 1170 developmental projects in cancer across 169 different targets. In addition, there is 1 suspended drug and another 138 drugs where development has been ceased. Learn More

  3. VEGF Signaling Pathway in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 253 companies plus partners who are today developing 348 VEGF signaling pathway targeting drugs in 1433 developmental projects in cancer across 164 different targets. In addition, there are 3 suspended drugs and another 151 drugs where development has been ceased. Learn More

  4. Vascular Targeting Agents: Emerging Competitors

    $1,950.00
    Published by BioSeeker Group on Feb 8th, 2005
    An update on the most recent advances made for vascular targeting agents that are now entering an exciting stage of development. Learn More

  5. TSLP Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 248 companies plus partners who are today developing 306 TSLP pathway targeting drugs in 1255 developmental projects in cancer across 179 different targets. In addition, there are 2 suspended drugs and another 174 drugs where development has been ceased. Learn More

  6. TSH Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 226 companies plus partners who are today developing 315 TSH pathway targeting drugs in 1330 developmental projects in cancer across 183 different targets. In addition, there are 4 suspended drugs and another 150 drugs where development has been ceased. Learn More

  7. Transcriptional Misregulation in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 292 companies plus partners who are today developing 350 transcriptional misregulation targeting drugs in 1432 developmental projects in cancer across 229 different targets. In addition, there are 6 suspended drugs and another 204 drugs where development has been ceased. Learn More

  8. Toll-Like Receptor Signaling Pathway in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 238 companies plus partners who are today developing 301 Toll-like Receptor signaling pathway targeting drugs in 996 developmental projects in cancer across 177 different targets. In addition, there are 6 suspended drugs and another 110 drugs where development has been ceased. Learn More

  9. TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 534 companies plus partners who are today developing 731 TNF-alpha pathway targeting drugs in 2597 developmental projects in cancer across 286 different targets. In addition, there are 5 suspended drugs and another 313 drugs where development has been ceased. Learn More

  10. The MAPK Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 343 companies plus partners who are today developing 463 The MAPK signaling pathway targeting drugs in 1699 developmental projects in cancer across 206 different targets. In addition, there are 2 suspended drugs and another 198 drugs where development has been ceased. Learn More

  11. The Latest Sales Figures in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 46 companies plus partners who are today developing 114 The Latest Sales Figures in Oncology drugs in 1477 developmental projects in cancer across 113 different targets. In addition, there are 2 suspended drugs and another 27 drugs where development has been ceased. Learn More

  12. TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 396 companies plus partners who are today developing 509 TGF-beta receptor pathway targeting drugs in 1845 developmental projects in cancer across 259 different targets. In addition, there are 2 suspended drugs and another 265 drugs where development has been ceased. Learn More

  13. TCR/CAR-T Therapies in Oncology Drug Pipeline Update

    $995.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 40 companies plus partners who are today developing 124 TCR/CAR-T drugs in 300 developmental projects in cancer across 58 different targets. In addition, there is 1 suspended drug and another 1 drugs where development has been ceased. Learn More

  14. Targeting Tight Junctions in Cancer Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 120 companies plus partners who are today developing 122 tight junction targeting drugs in 466 developmental projects in cancer across 107 different targets. In addition, there is 1 suspended drug and another 48 drugs where development has been ceased. Learn More

  15. Targeting Natural Killer Cell Mediated Cytotoxicity in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 252 companies plus partners who are today developing 318 targeting natural killer cell mediated cytotoxicity drugs in 1129 developmental projects in cancer across 179 different targets. In addition, there are 2 suspended drugs and another 95 drugs where development has been ceased. Learn More

  16. Targeting Metabolic Pathways in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 221 companies plus partners who are today developing 235 metabolic pathways targeting drugs in 590 developmental projects in cancer across 157 different targets. In addition, there are 2 suspended drugs and another 92 drugs where development has been ceased. Learn More

  17. Targeting Immune Checkpoints in Cancer Immunotherapy Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 120 companies plus partners who are today developing 227 immune checkpoints drugs in 835 developmental projects in cancer across 71 different targets. In addition, there are 4 suspended drugs and another 19 drugs where development has been ceased. Learn More

  18. Targeting Focal Adhesion for the Treatment of Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 488 companies plus partners who are today developing 739 focal adhesion targeting drugs in 2727 developmental projects in cancer across 268 different targets. In addition, there are 5 suspended drugs and another 315 drugs where development has been ceased. Learn More

  19. Targeting Cell Adhesion Molecules (CAMs) for the Treatment of Cancer Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 146 companies plus partners who are today developing 182 targeting CAMs drugs in 706 developmental projects in cancer across 124 different targets. In addition, there are 3 suspended drugs and another 49 drugs where development has been ceased. Learn More

  20. Target Atlas in Thyroid Cancer: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  21. Target Atlas in Sarcomas: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  22. Target Atlas in Renal Cancer: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  23. Target Atlas in Peritoneal Cancer: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  24. Target Atlas in Pancreatic Cancer: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  25. Target Atlas in Ovarian Cancer: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  26. Target Atlas in Oesophageal Cancer: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  27. Target Atlas in Neuroendocrine Tumors: A Competitive Outlook

    $1,495.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  28. Target Atlas in Nasopharyngeal Cancer: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  29. Target Atlas in Myeloma: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  30. Target Atlas in Myelodysplastic Syndrome: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  31. Target Atlas in Mesothelioma: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  32. Target Atlas in Melanoma: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  33. Target Atlas in Lymphoma: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  34. Target Atlas in Lung Cancer: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  35. Target Atlas in Liver Cancer: A Competitive Outlook

    $1,495.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  36. Target Atlas in Leukemia: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  37. Target Atlas in Hematological Cancers: A Competitive Outlook

    $2,950.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  38. Target Atlas in Head and Neck Cancer: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  39. Target Atlas in Gastrointestinal Cancer: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  40. Target Atlas in Fallopian Tube Cancer: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  41. Target Atlas in Endometrial Cancer: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  42. Target Atlas in Colorectal Cancer: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  43. Target Atlas in Breast Cancer: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  44. Target Atlas in Brain Cancer: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  45. Target Atlas in Bone Cancer: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  46. Target Atlas in Bladder Cancer: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  47. Target Atlas in Biliary Cancer: A Competitive Outlook

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  48. T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 355 companies plus partners who are today developing 469 T cell receptor pathway targeting drugs in 1756 developmental projects in cancer across 242 different targets. In addition, there are 7 suspended drugs and another 210 drugs where development has been ceased. Learn More

  49. RNAs (miRNA, RNAi & siRNA) in Oncology: Drug Pathway Analyzer

    $750.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 102 RNA (miRNA, RNAi & siRNA) drugs known to affect more than 168 specific intracellular signaling pathways for the treatment of more than 41 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 90 drug targets that are included in this drug-pathway analyzing tool. No less than 67 of these have been recorded with mutations and 16 drug targets have mutations which have been causally implicated in cancer. Learn More

  50. RIG-I-like Receptor Signaling Pathway in Cancer Drug Pipeline Update

    $750.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 78 companies plus partners who are today developing 55 RIG-I-like receptor signaling pathway targeting drugs in 166 developmental projects in cancer across 85 different targets. In addition, there is 1 suspended drug and another 33 drugs where development has been ceased. Learn More

  51. Renal Cancer Drug Pathway Analyzer

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 304 targeted molecular therapies known to affect more than 240 specific intracellular signaling pathways for the treatment of renal cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 223 drug targets that are included in this drug-pathway analyzing tool. No less than 215 of these have been recorded with mutations and 46 drug targets have mutations which have been causally implicated in cancer. Learn More

  52. RANKL Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 282 companies plus partners who are today developing 356 RANKL pathway targeting drugs in 1398 developmental projects in cancer across 155 different targets. In addition, there is 1 suspended drug and another 178 drugs where development has been ceased. Learn More

  53. Proteins in Oncology: Drug Pathway Analyzer

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 510 protein drugs known to affect more than 209 specific intracellular signaling pathways for the treatment of more than 97 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 200 drug targets that are included in this drug-pathway analyzing tool. No less than 181 of these have been recorded with mutations and 25 drug targets have mutations which have been causally implicated in cancer. Learn More

  54. Proteins in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 455 companies plus partners who are today developing 521 protein drugs in 914 developmental projects in cancer across 229 different targets. In addition, there are 2 suspended drugs and another 207 drugs where development has been ceased. Learn More

  55. Protein Kinase Inhibitors Drug Pathway Analyzer

    $2,995.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 1342 protein kinase inhibitor drugs known to affect more than 251 specific intracellular signaling pathways for the treatment of more than 160 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 287 drug targets that are included in this drug-pathway analyzing tool. No less than 280 of these have been recorded with mutations and 57 drug targets have mutations which have been causally implicated in cancer. Learn More

  56. Prostate Cancer Drug Pathway Analyzer

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 503 targeted molecular therapies known to affect more than 255 specific intracellular signaling pathways for the treatment of prostate cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 317 drug targets that are included in this drug-pathway analyzing tool. No less than 305 of these have been recorded with mutations and 58 drug targets have mutations which have been causally implicated in cancer. Learn More

  57. PI3K-Akt Signaling Pathway in Cancer Drug Pipeline Update

    $2,999.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 678 companies plus partners who are today developing 1154 PI3K-Akt signaling pathway targeting drugs in 3721 developmental projects in cancer across 349 different targets. In addition, there are 12 suspended drugs and another 452 drugs where development has been ceased. Learn More

  58. Peptides in Oncology: Drug Pathway Analyzer

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 256 peptide drugs known to affect more than 222 specific intracellular signaling pathways for the treatment of more than 94 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 221 drug targets that are included in this drug-pathway analyzing tool. No less than 218 of these have been recorded with mutations and 29 drug targets have mutations which have been causally implicated in cancer. Learn More

  59. Pancreatic Cancer Drug Pathway Analyzer

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 406 targeted molecular therapies known to affect more than 253 specific intracellular signaling pathways for the treatment of pancreatic cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 317 drug targets that are included in this drug-pathway analyzing tool. No less than 306 of these have been recorded with mutations and 62 drug targets have mutations which have been causally implicated in cancer. Learn More

  60. p53 Signaling Pathway in Cancer Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 120 companies plus partners who are today developing 108 p53 signaling pathway targeting drugs in 340 developmental projects in cancer across 84 different targets. In addition, there is 1 suspended drug and another 67 drugs where development has been ceased. Learn More

  61. Ovarian Cancer Drug Pathway Analyzer

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 439 targeted molecular therapies known to affect more than 250 specific intracellular signaling pathways for the treatment of ovarian cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 291 drug targets that are included in this drug-pathway analyzing tool. No less than 275 of these have been recorded with mutations and 51 drug targets have mutations which have been causally implicated in cancer. Learn More

  62. Orphan Drugs in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 476 companies plus partners who are today developing 665 orphan drugs in oncology drugs in 4085 developmental projects in cancer across 422 different targets. In addition, there are 15 suspended drugs and another 190 drugs where development has been ceased. Learn More

  63. Oncology Drug Pipeline Update - Online

    $7,950.00
    Published by BioSeeker Group on Jan 1st, 2016
    Get online access to competitive drug information for more than 10,500 drugs across 200+ indications in oncology via our intuitive guided searches, innovative filters, and the result presented in smart, online reports available for download. Learn More

  64. Oncology Drug Pipeline Update - Desktop App

    $14,850.00
    Published by BioSeeker Group on Mar 25th, 2014
    Get desktop access to competitive drug information formore than 9,300 drugs across 200+ indications in oncology via our intuitive guided searches, innovative filters, and the result presented in smart reports. Learn More

  65. Nucleic Acid Therapies in Oncology: Drug Pathway Analyzer

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 373 nucleic acid drugs known to affect more than 228 specific intracellular signaling pathways for the treatment of more than 91 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 220 drug targets that are included in this drug-pathway analyzing tool. No less than 189 of these have been recorded with mutations and 36 drug targets have mutations which have been causally implicated in cancer. Learn More

  66. Nucleic Acid Therapies in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 308 companies plus partners who are today developing 381 nucleic acid therapy drugs in 775 developmental projects in cancer across 251 different targets. In addition, there are 9 suspended drugs and another 211 drugs where development has been ceased. Learn More

  67. Notch Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 335 companies plus partners who are today developing 416 Notch pathway targeting drugs in 1497 developmental projects in cancer across 232 different targets. In addition, there are 4 suspended drugs and another 236 drugs where development has been ceased. Learn More

  68. NOD-like Receptor Signaling Pathway in Cancer Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 113 companies plus partners who are today developing 88 NOD-like receptor signaling pathway targeting drugs in 272 developmental projects in cancer across 95 different targets. In addition, there is 1 suspended drug and another 58 drugs where development has been ceased. Learn More

  69. New Concepts in Cancer Therapeutics

    $2,450.00
    Published by BioSeeker Group on Dec 30th, 2005
    There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 20 years ago. Many of the new classes of agents.... Learn More

  70. Neuroendocrine Tumors Drug Pathway Analyzer

    $750.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 97 targeted molecular therapies known to affect more than 222 specific intracellular signaling pathways for the treatment of neuroendocrine tumors. The rational for this plethora of treatment strategies is based on our increasing understanding of the 114 drug targets that are included in this drug-pathway analyzing tool. No less than 106 of these have been recorded with mutations and 36 drug targets have mutations which have been causally implicated in cancer. Learn More

  71. mTOR Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 221 companies plus partners who are today developing 278 mTOR signaling pathway targeting drugs in 1136 developmental projects in cancer across 127 different targets. In addition, there is 1 suspended drug and another 89 drugs where development has been ceased. Learn More

  72. Modulators of the Actin Cytoskeleton for the Treatment of Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 280 companies plus partners who are today developing 427 targeting actin cytoskeleton modulators drugs in 1598 developmental projects in cancer across 187 different targets. In addition, there is 1 suspended drug and another 178 drugs where development has been ceased. Learn More

  73. Mitochondrial Drugs in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 341 companies plus partners who are today developing 373 mitochondrial drugs in oncology drugs in 1212 developmental projects in cancer across 223 different targets. In addition, there are 5 suspended drugs and another 156 drugs where development has been ceased. Learn More

  74. MicroRNAs in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 567 companies plus partners who are today developing 841 microRNA targeting and competitor drugs in 3023 developmental projects in cancer across 289 different targets. In addition, there are 5 suspended drugs and another 343 drugs where development has been ceased. Learn More

  75. Melanoma: Analytical Tool

    $4,750.00
    Published by BioSeeker Group on Aug 22nd, 2016
    This Analytical Tool transforms your computer’s desktop into a high capacity workbench within the area of melanoma. It supports you in making reports, presentations and preparing conference attendance and it is all done via an easy to use ’point and click’ interface. Learn More

  76. Melanoma Therapeutics: Which Strategy Will Take Us There?

    $2,450.00
    Published by BioSeeker Group on Jul 18th, 2005
    Melanoma drug development has and will continue to have a strong focus on target therapy such as vaccines, monoclonal antibodies, dendritic cells, and gene therapy. Learn More

  77. Melanoma Drug Pathway Analyzer

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 387 targeted molecular therapies known to affect more than 251 specific intracellular signaling pathways for the treatment of melanoma. The rational for this plethora of treatment strategies is based on our increasing understanding of the 283 drug targets that are included in this drug-pathway analyzing tool. No less than 265 of these have been recorded with mutations and 54 drug targets have mutations which have been causally implicated in cancer. Learn More

  78. Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

    Regular Price: $1,950.00

    Special Price: $975.00

    Published by BioSeeker Group on Jun 12th, 2013
    In-depth pipeline analytics of melanoma drugs showing you where the competition is, what is first-in-class and is first-in-class the best-in-class?, indication expansion opportunities and much more Learn More

  79. Market Development in Anti-virals:What is Next?

    $495.00
    Published by BioSeeker Group on Aug 24th, 2004
    This analysis deals with 26 of the most promising pharmaceutical companies with anti-viral drugs on the market. Indication by indication is measured by number of current therapies, present sales and sales development. Learn More

  80. Lymphoma: Analytical Tool

    $4,750.00
    Published by BioSeeker Group on Aug 22nd, 2016
    This Analytical Tool transforms your computer’s desktop into a high capacity workbench within the area of lymphoma. It supports you in making reports, presentations and preparing conference attendance and it is all done via an easy to use ’point and click’ interface. Learn More

  81. Lymphoma Drug Pathway Analyzer

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 563 targeted molecular therapies known to affect more than 244 specific intracellular signaling pathways for the treatment of lymphoma. The rational for this plethora of treatment strategies is based on our increasing understanding of the 288 drug targets that are included in this drug-pathway analyzing tool. No less than 267 of these have been recorded with mutations and 65 drug targets have mutations which have been causally implicated in cancer. Learn More

  82. Lung Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 552 companies plus partners who are today developing 809 lung cancer drugs in 884 developmental projects in cancer across 431 different targets. In addition, there are 10 suspended drugs and another 267 drugs where development has been ceased. Learn More

  83. Lung Cancer Drug Pathway Analyzer

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 733 targeted molecular therapies known to affect more than 261 specific intracellular signaling pathways for the treatment of lung cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 393 drug targets that are included in this drug-pathway analyzing tool. No less than 369 of these have been recorded with mutations and 65 drug targets have mutations which have been causally implicated in cancer. Learn More

  84. Liver Cancer Drug Pathway Analyzer

    $1,495.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 240 targeted molecular therapies known to affect more than 236 specific intracellular signaling pathways for the treatment of liver cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 205 drug targets that are included in this drug-pathway analyzing tool. No less than 197 of these have been recorded with mutations and 47 drug targets have mutations which have been causally implicated in cancer. Learn More

  85. Leukemia: Analytical Tool

    $4,750.00
    Published by BioSeeker Group on Aug 22nd, 2016
    This Analytical Tool transforms your computer’s desktop into a high capacity workbench within the area of leukemia. It supports you in making reports, presentations and preparing conference attendance and it is all done via an easy to use ’point and click’ interface. Learn More

  86. Leukemia Drug Pathway Analyzer

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 620 targeted molecular therapies known to affect more than 248 specific intracellular signaling pathways for the treatment of leukemia. The rational for this plethora of treatment strategies is based on our increasing understanding of the 309 drug targets that are included in this drug-pathway analyzing tool. No less than 300 of these have been recorded with mutations and 73 drug targets have mutations which have been causally implicated in cancer. Learn More

  87. Leptin Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 410 companies plus partners who are today developing 537 Leptin pathway targeting drugs in 1840 developmental projects in cancer across 213 different targets. In addition, there are 3 suspended drugs and another 229 drugs where development has been ceased. Learn More

  88. Large Pharma:2004 a year of Progress

    $1,950.00
    Published by BioSeeker Group on Jan 18th, 2005
    BioSeeker Group analyzes the progress made by the large pharmaceutical companies top oncology drug candidates whom has reached Phase III clinical evaluation. Learn More

  89. Kit Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 248 companies plus partners who are today developing 346 Kit receptor pathway targeting drugs in 1506 developmental projects in cancer across 178 different targets. In addition, there are 3 suspended drugs and another 176 drugs where development has been ceased. Learn More

  90. Jak-STAT Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 341 companies plus partners who are today developing 473 Jak-STAT signaling pathway targeting drugs in 1185 developmental projects in cancer across 203 different targets. In addition, there are 8 suspended drugs and another 141 drugs where development has been ceased. Learn More

  91. Interfering With the ECM-Receptor Interaction for the Treatment of Cancer Drug Pipeline Update

    $750.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 67 companies plus partners who are today developing 50 targeting ECM-receptor interaction drugs in 121 developmental projects in cancer across 52 different targets. In addition, there is 1 suspended drug and another 28 drugs where development has been ceased. Learn More

  92. Interfering With Cytokine-Cytokine Receptor Interaction for the Treatment of Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 529 companies plus partners who are today developing 854 cytokine-cytokine receptor interaction interference drugs in 2473 developmental projects in cancer across 310 different targets. In addition, there are 10 suspended drugs and another 303 drugs where development has been ceased. Learn More

  93. Immunotherapy in Oncology: Drug Pathway Analyzer

    $3,675.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 1183 immunotherapy drugs known to affect more than 237 specific intracellular signaling pathways for the treatment of more than 175 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 452 drug targets that are included in this drug-pathway analyzing tool. No less than 419 of these have been recorded with mutations and 57 drug targets have mutations which have been causally implicated in cancer. Learn More

  94. IL-9 Signaling Pathway in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 83 companies plus partners who are today developing 88 IL-9 pathway targeting drugs in 366 developmental projects in cancer across 67 different targets. In addition, there is 1 suspended drug and another 35 drugs where development has been ceased. Learn More

  95. IL-7 Signaling Pathway in Oncology Drug Pipeline Update

    $750.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 90 companies plus partners who are today developing 95 IL-7 pathway targeting drugs in 389 developmental projects in cancer across 85 different targets. In addition, there is 1 suspended drug and another 36 drugs where development has been ceased. Learn More

  96. IL-6 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 378 companies plus partners who are today developing 467 IL-6 pathway targeting drugs in 1579 developmental projects in cancer across 198 different targets. In addition, there are 2 suspended drugs and another 203 drugs where development has been ceased. Learn More

  97. IL-5 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 163 companies plus partners who are today developing 209 IL-5 pathway targeting drugs in 891 developmental projects in cancer across 146 different targets. In addition, there are 2 suspended drugs and another 86 drugs where development has been ceased. Learn More

  98. IL-4 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 208 companies plus partners who are today developing 274 IL-4 pathway targeting drugs in 988 developmental projects in cancer across 161 different targets. In addition, there are 4 suspended drugs and another 105 drugs where development has been ceased. Learn More

  99. IL-3 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 257 companies plus partners who are today developing 339 IL-3 pathway targeting drugs in 1225 developmental projects in cancer across 164 different targets. In addition, there are 4 suspended drugs and another 131 drugs where development has been ceased. Learn More

  100. IL-2 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 344 companies plus partners who are today developing 449 IL-2 pathway targeting drugs in 1619 developmental projects in cancer across 192 different targets. In addition, there are 6 suspended drugs and another 183 drugs where development has been ceased. Learn More

  101. IL-1 Signaling Pathway in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 111 companies plus partners who are today developing 113 IL-1 pathway targeting drugs in 415 developmental projects in cancer across 96 different targets. In addition, there are 2 suspended drugs and another 55 drugs where development has been ceased. Learn More

  102. ID Signaling Pathway in Oncology Drug Pipeline Update

    $750.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 117 companies plus partners who are today developing 114 ID pathway targeting drugs in 493 developmental projects in cancer across 104 different targets. In addition, there is 1 suspended drug and another 62 drugs where development has been ceased. Learn More

  103. HIF-1 Signaling Pathway in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 478 companies plus partners who are today developing 658 HIF-1 signaling pathway targeting drugs in 2402 developmental projects in cancer across 236 different targets. In addition, there are 4 suspended drugs and another 246 drugs where development has been ceased. Learn More

  104. Hematological Cancers Drug Pathway Analyzer

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 1079 targeted molecular therapies known to affect more than 260 specific intracellular signaling pathways for the treatment of hematological cancers. The rational for this plethora of treatment strategies is based on our increasing understanding of the 450 drug targets that are included in this drug-pathway analyzing tool. No less than 419 of these have been recorded with mutations and 87 drug targets have mutations which have been causally implicated in cancer. Learn More

  105. Hedgehog Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 163 companies plus partners who are today developing 203 Hedgehog pathway targeting drugs in 883 developmental projects in cancer across 133 different targets. In addition, there are 3 suspended drugs and another 90 drugs where development has been ceased. Learn More

  106. Head and Neck Cancer Drug Pathway Analyzer

    $1,495.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 236 targeted molecular therapies known to affect more than 246 specific intracellular signaling pathways for the treatment of head and neck cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 211 drug targets that are included in this drug-pathway analyzing tool. No less than 199 of these have been recorded with mutations and 43 drug targets have mutations which have been causally implicated in cancer. Learn More

  107. HCV R&D and Business Development Database

    $1,950.00
    Published by BioSeeker Group on Jun 22nd, 2004
    This CD-ROM product is one of the most comprehensive and up to date information sources on chronic hepatitis C virus R&D and business development. Learn More

  108. GnRH Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 185 companies plus partners who are today developing 234 GnRH signaling pathway targeting drugs in 844 developmental projects in cancer across 126 different targets. In addition, there is 1 suspended drug and another 86 drugs where development has been ceased. Learn More

  109. Gastrointestinal Cancer Drug Pathway Analyzer

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 292 targeted molecular therapies known to affect more than 241 specific intracellular signaling pathways for the treatment of gastrointestinal cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 174 drug targets that are included in this drug-pathway analyzing tool. No less than 167 of these have been recorded with mutations and 45 drug targets have mutations which have been causally implicated in cancer. Learn More

  110. Gap Junctions in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 280 companies plus partners who are today developing 396 gap junctions targeting drugs in 1561 developmental projects in cancer across 170 different targets. In addition, there is 1 suspended drug and another 167 drugs where development has been ceased. Learn More

  111. FSH Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 273 companies plus partners who are today developing 369 FSH pathway targeting drugs in 1441 developmental projects in cancer across 165 different targets. In addition, there are 2 suspended drugs and another 167 drugs where development has been ceased. Learn More

  112. Fierce 15 in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 72 companies plus partners who are today developing 201 Fierce 15 drugs in 600 developmental projects in cancer across 130 different targets. In addition, there are 2 suspended drugs and another 34 drugs where development has been ceased. Learn More

  113. Fc Epsilon RI Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 182 companies plus partners who are today developing 255 Fc epsilon RI signaling pathway targeting drugs in 966 developmental projects in cancer across 148 different targets. In addition, there are 2 suspended drugs and another 84 drugs where development has been ceased. Learn More

  114. ErbB Signaling Pathway in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 366 companies plus partners who are today developing 528 ErbB signaling pathway targeting drugs in 1896 developmental projects in cancer across 187 different targets. In addition, there is 1 suspended drug and another 202 drugs where development has been ceased. Learn More

  115. Epigenetic Therapy in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 101 companies plus partners who are today developing 129 epigenetic therapy drugs in 477 developmental projects in cancer across 57 different targets. In addition, there is 1 suspended drug and another 36 drugs where development has been ceased. Learn More

  116. EGFR1 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 554 companies plus partners who are today developing 852 EGFR1 pathway targeting drugs in 3067 developmental projects in cancer across 295 different targets. In addition, there are 5 suspended drugs and another 379 drugs where development has been ceased. Learn More

  117. Drug Target Atlas in Oncology

    $7,950.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  118. Current and Future Therapies for Colorectal Cancer - A Therapeutic & Competitive Insight

    $1,950.00
    Published by BioSeeker Group on Sep 19th, 2005
    Colorectal cancer (CRC) is the second most common cause of cancer death in much of the developed world. Cancer-related mortality is slowly decreasing as a result of better detection and significant advances in the treatment of advanced colorectal cancer over the past 5 years. Learn More

  119. Conjugated Drugs in Oncology: Drug Pathway Analyzer

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 394 conjugated drugs known to affect more than 211 specific intracellular signaling pathways for the treatment of more than 109 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 211 drug targets that are included in this drug-pathway analyzing tool. No less than 190 of these have been recorded with mutations and 36 drug targets have mutations which have been causally implicated in cancer. Learn More

  120. Conjugated Drugs in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 295 companies plus partners who are today developing 451 conjugated drugs in oncology drugs in 1015 developmental projects in cancer across 238 different targets. In addition, there are 2 suspended drugs and another 145 drugs where development has been ceased. Learn More

  121. Competitive Outlook on HCV: What to Know and Expect in R&D and Business Development

    $999.00
    Published by BioSeeker Group on Jun 22nd, 2004
    A fresh look on both the current world status of R&D and business development in HCV. Our research and analysis is built on more than 150 companies from over 18 different countries and include more than 160 pipline drugs in development for HCV. Learn More

  122. Colorectal Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 426 companies plus partners who are today developing 509 drugs targeting colorectal cancer in development. across 346 different targets. In addition, there are 6 suspended drugs and another 211 drugs where development has been ceased. Learn More

  123. Colorectal Cancer Drug Pathway Analyzer

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 516 targeted molecular therapies known to affect more than 252 specific intracellular signaling pathways for the treatment of colorectal cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 313 drug targets that are included in this drug-pathway analyzing tool. No less than 301 of these have been recorded with mutations and 60 drug targets have mutations which have been causally implicated in cancer. Learn More

  124. Chemokine Signaling Pathway in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 232 companies plus partners who are today developing 323 chemokine signaling pathway targeting drugs in 1189 developmental projects in cancer across 177 different targets. In addition, there are 3 suspended drugs and another 127 drugs where development has been ceased. Learn More

  125. Cell Cycle Targeting in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 180 companies plus partners who are today developing 190 targeting the cell cycle drugs in 687 developmental projects in cancer across 131 different targets. In addition, there are 2 suspended drugs and another 123 drugs where development has been ceased. Learn More

  126. Cancer Stem Cells Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 441 companies plus partners who are today developing 648 cancer stem cells and developmental pathways drugs in 2272 developmental projects in cancer across 329 different targets. In addition, there are 6 suspended drugs and another 308 drugs where development has been ceased. Learn More

  127. Cancer Drugs in the FDA Fast Lane Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 142 companies plus partners who are today developing 171 cancer drugs in the FDA fast lane drugs in 1660 developmental projects in cancer across 177 different targets. In addition, there are 7 suspended drugs and another 65 drugs where development has been ceased. Learn More

  128. Calcium Signaling Pathway in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 276 companies plus partners who are today developing 335 calcium signaling pathway targeting drugs in 1110 developmental projects in cancer across 145 different targets. In addition, there is 1 suspended drug and another 130 drugs where development has been ceased. Learn More

  129. Breast Cancer: Analytical Tool

    $4,750.00
    Published by BioSeeker Group on Aug 22nd, 2016
    This Analytical Tool transforms your computer’s desktop into a high capacity workbench within the area of breast cancer. It supports you in making reports, presentations and preparing conference attendance and it is all done via an easy to use ’point and click’ interface. Learn More

  130. Breast Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 636 companies plus partners who are today developing 706 drugs targeting breast cancer in development. across 469 different targets. In addition, there are 7 suspended drugs and another 242 drugs where development has been ceased. Learn More

  131. Breast Cancer Drug Pathway Analyzer

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 745 targeted molecular therapies known to affect more than 262 specific intracellular signaling pathways for the treatment of breast cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 377 drug targets that are included in this drug-pathway analyzing tool. No less than 358 of these have been recorded with mutations and 63 drug targets have mutations which have been causally implicated in cancer. Learn More

  132. Breast Cancer - Therapeutic And Competitive Insights

    $1,950.00
    Published by BioSeeker Group on Feb 28th, 2007
    Gain insight into the current challenges and commercial opportunities associated with breast cancer therapy. Learn More

  133. Brain Cancer Drug Pathway Analyzer

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 332 targeted molecular therapies known to affect more than 246 specific intracellular signaling pathways for the treatment of brain cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 235 drug targets that are included in this drug-pathway analyzing tool. No less than 229 of these have been recorded with mutations and 51 drug targets have mutations which have been causally implicated in cancer. Learn More

  134. Bladder Cancer Drug Pathway Analyzer

    $1,495.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 141 targeted molecular therapies known to affect more than 219 specific intracellular signaling pathways for the treatment of bladder cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 133 drug targets that are included in this drug-pathway analyzing tool. No less than 123 of these have been recorded with mutations and 30 drug targets have mutations which have been causally implicated in cancer. Learn More

  135. Biosimilars in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 90 companies plus partners who are today developing 213 biosimilar drugs in 472 developmental projects in cancer across 17 different targets. In addition, there is 1 suspended drug and another 1 drugs where development has been ceased. Learn More

  136. Biologicals in Oncology: Drug Pathway Analyzer

    $3,675.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 2306 biological drugs known to affect more than 269 specific intracellular signaling pathways for the treatment of more than 175 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 674 drug targets that are included in this drug-pathway analyzing tool. No less than 607 of these have been recorded with mutations and 76 drug targets have mutations which have been causally implicated in cancer. Learn More

  137. Biologicals in Oncology Drug Pipeline Update

    $3,675.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 1371 companies plus partners who are today developing 2823 biological drugs in 6088 developmental projects in cancer across 801 different targets. In addition, there are 25 suspended drugs and another 1050 drugs where development has been ceased. Learn More

  138. Bio-Europe 2014 Cancer Drug Pipeline Update 2015

    $4,425.00
    Published by BioSeeker Group on Jan 5th, 2015
    BioSeeker Group have identified 292 companies plus partners who are today developing 1381 BIO-Europe 2014 cancer drugs in 4487 developmental projects in cancer across 629 different targets. In addition, there are 18 suspended drugs and another 880 drugs where development has been ceased. Learn More

  139. B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 309 companies plus partners who are today developing 424 B cell receptor pathway targeting drugs in 1700 developmental projects in cancer across 198 different targets. In addition, there are 5 suspended drugs and another 154 drugs where development has been ceased. Learn More

  140. Apoptosis: Promise or deception?

    $1,950.00
    Published by BioSeeker Group on May 7th, 2005
    In this publication, BioSeeker Group analyzes the latest progress made for 25 drug candidates targeting the cell death pathway, apoptosis. Additionally, more early stage candidates are also under investigation, which brings the total number of companies interested in this field to around 40. Learn More

  141. Antifungals: 2004 and Beyond

    $1,950.00
    Published by BioSeeker Group on Oct 19th, 2004
    Overview of the most common fungal diseases, already marketed antifungal agents, details from recent studies on approved agents, and information on the recent activities of companies with developmental antifungals. Learn More

  142. Antibodies in Oncology: Drug Pathway Analyzer

    $2,250.00
    Published by BioSeeker Group on Aug 9th, 2016
    There are today at least 1114 antibody drugs known to affect more than 216 specific intracellular signaling pathways for the treatment of more than 144 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 345 drug targets that are included in this drug-pathway analyzing tool. No less than 322 of these have been recorded with mutations and 38 drug targets have mutations which have been causally implicated in cancer. Learn More

  143. Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 455 companies plus partners who are today developing 569 Androgen Receptor drugs in 1838 developmental projects in cancer across 228 different targets. In addition, there are 2 suspended drugs and another 258 drugs where development has been ceased. Learn More

  144. Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 378 companies plus partners who are today developing 534 Alpha6Beta4 integrin pathway targeting drugs in 1796 developmental projects in cancer across 186 different targets. In addition, there is 1 suspended drug and another 209 drugs where development has been ceased. Learn More

  145. Adherens Junction Targeting in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 277 companies plus partners who are today developing 357 targeting adherens junctions drugs in 1199 developmental projects in cancer across 134 different targets. In addition, there is 1 suspended drug and another 136 drugs where development has been ceased. Learn More

  146. 2015 BIO Asia Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Mar 9th, 2015
    BioSeeker Group have identified at least 75 companies represented at the 2015 BIO Asia meeting linked to the active development of 816 drugs in 3,092 developmental projects in cancer across 413 different targets. Learn More

146 Item(s)

per page

Set Ascending Direction